Exelixis (EXEL) Stock Price, News & Analysis

Company Overview

Exelixis, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of small molecule therapies for the treatment of cancer. Since its founding in 1994, Exelixis has been focused on applying cutting-edge genomics and molecular biology to identify novel targets and advance therapeutic candidates through clinical development. The company’s mission centers on delivering life-extending medicines to patients with serious diseases, with an emphasis on improving outcomes for individuals living with various forms of cancer.

The company’s core commercial products include Cometriq (cabozantinib) for medullary thyroid cancer and Cabometyx (cabozantinib) for renal cell carcinoma and hepatocellular carcinoma. Exelixis also co-develops and co-commercializes Cotellic (cobimetinib) in collaboration with Roche, which is approved for certain forms of metastatic melanoma. In addition to its marketed therapies, Exelixis maintains a robust pipeline of investigational agents targeting key pathways in oncology. Ongoing clinical programs explore the use of novel compounds in combination regimens and as monotherapies in multiple solid tumor types.

Headquartered in Alameda, California, Exelixis operates research and development facilities in the United States, Europe, and Asia. The company’s global footprint is supported by strategic collaborations with industry partners such as Ipsen, Takeda, and Roche, which help expand patient access and accelerate clinical trial execution across diverse geographies. Exelixis leverages a partnership-driven model to maximize the reach of its therapies while retaining in-house expertise in small molecule drug discovery and development.

Under the leadership of President and Chief Executive Officer Michael Morrissey, Exelixis continues to pursue innovation in oncology with a focus on both advancing existing assets and discovering new candidates. The executive team combines scientific rigor with commercial acumen to navigate regulatory pathways and bring life-saving treatments to market. With a commitment to research excellence and patient-centric development, Exelixis remains at the forefront of efforts to transform cancer care through precision medicine.

Key Stats

• Today's Range: $44.12 to $48.74
• 50-Day Range: $36.17 to $46.26
• 52-Week Range: $21.86 to $49.62
• Volume: 6.04 million shs
• Average Volume: 2.49 million shs
• Market Capitalization: $12.52 billion
• P/E Ratio: 20.87
• Dividend Yield: N/A
• Price Target: $43.56
• Consensus Rating: Moderate Buy

Exelixis Stock Analysis - MarketRank™

Exelixis scored higher than 95% of companies evaluated by MarketBeat, and ranked 61st out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Exelixis has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 13 buy ratings, 6 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Exelixis has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 25.00%

Earnings Growth

Earnings for Exelixis are expected to grow by 25.00% in the coming year, from $2.04 to $2.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exelixis is 20.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exelixis is 20.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.63.

Price to Earnings Growth Ratio

Exelixis has a PEG Ratio of 0.93. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Exelixis has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.73% of the float of Exelixis has been sold short.

Short Interest Ratio / Days to Cover

Exelixis has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Exelixis has recently increased by 9.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exelixis does not currently pay a dividend.

Dividend Growth

Exelixis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.63

Percentage of Shares Shorted

7.73% of the float of Exelixis has been sold short.

Short Interest Ratio / Days to Cover

Exelixis has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Exelixis has recently increased by 9.56%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.12

News Sentiment

Exelixis has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Exelixis this week, compared to 15 articles on an average week.

Search Interest

Only 19 people have searched for EXEL on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.

MarketBeat Follows

16 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,024,817.00 in company stock.

Percentage Held by Insiders

Only 2.82% of the stock of Exelixis is held by insiders.

Percentage Held by Institutions

85.27% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EXEL Stock Analysis - Frequently Asked Questions

How have EXEL shares performed this year?

Exelixis' stock was trading at $33.30 at the beginning of 2025. Since then, EXEL stock has increased by 37.9% and is now trading at $45.91.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) released its earnings results on Tuesday, February, 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by $0.03. Exelixis had a trailing twelve-month return on equity of 28.81% and a net margin of 27.99%.
Read the conference call transcript.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exelixis investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Humana (HUM), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 2/11/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EXEL
• CIK: 939767
• Web: www.exelixis.com
• Phone: (650) 837-7000
• Fax: 650-837-8300
• Employees: 1,147
• Year Founded: 1994

Price Target and Rating

• Average Stock Price Target: $43.56
• High Stock Price Target: $60.00
• Low Stock Price Target: $29.00
• Potential Upside/Downside: -5.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.52
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.20
• Trailing P/E Ratio: 20.87
• Forward P/E Ratio: 22.50
• P/E Growth: 0.93
• Net Income: $521.27 million
• Net Margins: 27.99%
• Pretax Margin: 36.46%
• Return on Equity: 28.81%
• Return on Assets: 21.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.50
• Quick Ratio: 3.44

Sales & Book Value

• Annual Sales: $2.17 billion
• Price / Sales: 5.77
• Cash Flow: $1.92 per share
• Price / Cash Flow: 23.96
• Book Value: $7.86 per share
• Price / Book: 5.84

Miscellaneous

• Outstanding Shares: 272,710,000
• Free Float: 265,018,000
• Market Cap: $12.52 billion
• Optionable: Optionable
• Beta: 0.28